

News Release

FOR IMMEDIATE RELEASE

30 July 2010

Contact: **Neal G. Koller**
President & CEO
Board of Directors
+1 (443) 994-0101

PHARMACEUTICAL INDUSTRY MARKETING EXECUTIVE & VAAN PROFESSIONAL ANGEL GROUP MEMBER ELECTED TO PLUROGEN BOARD OF DIRECTORS

(Charlottesville, VA, 30 July 2010) – PluroGen Therapeutics, Inc. is pleased to announce that Wendy Yarno has been elected to the PluroGen Board of Directors.

Ms. Yarno joins the PluroGen board continuing her distinguished career in life sciences. She has over 26 years experience in the pharmaceutical industry with Johnson & Johnson and Merck & Co., Inc. where she has held a number of executive positions in the marketing, sales, human resources and policy areas. Ms. Yarno most recently was Executive Vice President and Chief Marketing Officer at Merck & Co., Inc., and retired from Merck in 2008.

She is currently on the Board of Directors of St. Jude Medical (NYSE: STJ) a medical device company headquartered in Minneapolis, MN, and ADial Pharmaceuticals in Charlottesville, VA. Additionally, Ms. Yarno is on the Board of Advisors of HemoShear, LLC., OpenQ, LLC. and the University of Virginia Patent Foundation. She earned an MBA from Temple University in Philadelphia, PA, and a B.S. in Marketing from Portland State University in Portland, OR.

Commenting on Ms Yarno's joining the Plurogen Board of Directors, Neal G. Koller, President & CEO of PluroGen, said "PluroGen is honored and very pleased to have Ms. Yarno join our Board of Directors. Her deep and broad experience, relationships and understanding of the life science industry will add considerably to PluroGen's expertise and capabilities."

About PluroGen Therapeutics, Inc.

PluroGen is a burn, wound, and skin care company commercializing its multiple patent-protected technology platforms. The Company's primary platform is its core PluroGel® technology which provides paradigm-shifting, superior and differentiated physical, bio-impact, and multi-function products. PluroGel® is University developed and is in routine use at the University, having shown superior results on more than 10,000 patients in two different patient populations - severe burns and wounds. PluroGen's three technology platforms are configured to deliver a variety of medicinal and beneficial compounds covering the six key areas of treatment in tissue management and healing: 1. Cleansing; 2. Anti-Infection; 3. Reduced Pain; 4. Anti-Inflammation; 5. Tissue salvage; 6. Tissue regeneration.

PluroGen has a strong new product pipeline including PluroGel® Barrier Gels and Dressings, PluroGel® branded topical antimicrobial prescription products and PluroGel® co-branded products with select commercial partners.

PluroGen's senior management, operations team, boards and principal investigators are all recognized global commercial and clinical leaders in PluroGen's target markets of burn and wound care.

For more information about PluroGen Therapeutics, Inc., visit the Company's web site at www.plurogen.com.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company's reports filed with the U.S. Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or otherwise.